GLP-1 peptides like Ozempic and Mounjaro have moved from medical journals into general conversation in less than a decade. The mechanism, however, is rarely explained in accessible terms. This article translates the research into plain English without sacrificing accuracy — useful for researchers who need to explain the class to colleagues, students, or stakeholders.
Start with the gut hormone GLP-1
Your body makes a hormone called GLP-1 — glucagon-like peptide-1. The intestines release it after meals. Its job: tell the rest of the body “food just arrived.” That signal travels via the bloodstream to several places and produces several effects.
The three effects GLP-1 has
When GLP-1 signal arrives at its receptors, three things happen:
- Insulin gets released from the pancreas — but only when blood sugar is already elevated. This is “glucose-dependent” insulin release. It corrects high blood sugar without causing low blood sugar.
- The stomach empties more slowly — food stays in the stomach longer, which keeps you feeling full for hours instead of an hour.
- The brain registers fullness — GLP-1 receptors in the brain (particularly the hypothalamus and brainstem) reduce hunger signals and increase satiety.
That’s the entire mechanism in three sentences. Everything else is engineering.
Why your natural GLP-1 doesn’t keep working
Natural GLP-1 only lasts 1–2 minutes in your bloodstream. An enzyme called DPP-4 immediately chops it up. After a meal, your gut produces a burst of GLP-1, that burst gets degraded fast, and you’re back to baseline hunger within an hour or two.
What Ozempic does differently
Ozempic is semaglutide — a synthetic version of GLP-1 that is engineered to resist degradation and to last for days instead of minutes. Two changes do the heavy lifting:
- The molecule is slightly modified so DPP-4 can’t chop it up easily
- A fatty-acid sidechain hooks onto serum albumin (a blood protein) and rides around with it, releasing slowly
Result: one weekly injection gives you continuous GLP-1 receptor activation for seven days. The three natural effects — slower gastric emptying, glucose-dependent insulin, brain satiety — are sustained over the whole week.
What Mounjaro does on top of that
Mounjaro is tirzepatide — same general idea, but it activates two receptors instead of one. The second receptor is for a different gut hormone called GIP. GIP adds:
- Better insulin response coordination
- Direct effects on fat tissue lipid handling
- Possibly less nausea than equivalent GLP-1 doses
Two receptors = two metabolic levers. In trials, this produces about 50% more weight loss than GLP-1 alone (semaglutide).
What retatrutide adds beyond that
Retatrutide activates three receptors: GLP-1, GIP, and glucagon. The glucagon receptor sounds counterintuitive — glucagon normally raises blood sugar. But glucagon also burns calories through the liver. So the GLP-1/GIP arms cut your appetite (eat less), and the glucagon arm increases energy expenditure (burn more).
This is why retatrutide produces ~24% weight loss in phase 2 trials, while semaglutide produces ~15% in phase 3. The triple agonist hits both sides of the energy equation.
The “feeling full” effect explained
The most-cited subjective effect is reduced appetite. This isn’t psychological — it’s neurochemical. GLP-1 receptors in the brain communicate with hunger circuits that evolved to drive food-seeking behaviour. When those receptors are activated continuously, the hunger drive is dampened. Subjects describe being “less interested in food” rather than “willing themselves not to eat.”
The “stomach feels full” effect
Separately, the slower gastric emptying means a normal-sized meal sits in your stomach for hours longer than it normally would. This produces a physical sensation of fullness that supports reduced intake.
Why side effects happen
The same mechanisms that produce the benefit produce the side effects. Slowed stomach emptying causes nausea. Reduced appetite causes nutritional inadequacy if not managed. Most side effects are mild-to-moderate and reduce over time as the system adapts to the new signalling pattern.
What happens when you stop
The receptor activation ends. Hunger returns. Gastric emptying speeds up. The metabolic adaptation that drove weight loss reverses, and most subjects regain a substantial fraction of the lost weight within 6-12 months unless they sustain the changes through other means. This is why long-term protocols use these molecules continuously, not as a “course.”
That’s the entire story
GLP-1 peptides work by mimicking a gut hormone that already exists in your body, engineered to last for days instead of minutes. They reduce hunger, slow stomach emptying, and improve insulin response. Dual and triple agonists add receptors to the same fundamental approach.
Chempeptides supplies HPLC-verified GLP-1 class peptides for research applications — see the catalogue and our Ozempic article for deeper mechanism detail.
Research use only.